Using whole-genome sequencing to research deeply into our DNA has led to the discovery that all disease is linked to genetic mutations so that instead of trying to treat disease symptoms, we can now target the mutations causing them. This is personalised medicine. Read more about the outstanding work of the Garvan Institute, providing untold hope for sarcoma patients.
https://www.garvan.org.au/research/diseases/sarcoma/research
The sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, has identified a potential new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and adolescents, and a tumour known by its aggressiveness and tendency to metastasise.
Researchers have found that Ewing sarcoma cells die if an enzyme called CDK12 is knocked out genetically or chemically inhibited. What’s more, when a CDK12 inhibitor is combined with another drug, called a PARP inhibitor, the two drugs double down to deliver a lethal punch to Ewing sarcoma cells.
https://www.sciencedaily.com/releases/2018/01/180125230343.htm
The 2018 Australian Sarcoma Annual Scientific Meeting will be held in Perth on Friday 12th and Saturday 13th of October 2018.
ASSG have four grants on offer funded by generous donors, and are awarded for direct research costs. Selection criteria include track record and project feasibility, innovation and excellence. Please click on the links below for individual grant information.
The Johanna Sewell Sarcoma Research Grant $50,000 for one year
The Leon Stone Sarcoma Research Grant $20,000 for one year
The Xavier Krikori Sarcoma Research Grant $20,000 for one year
The Hannah’s Chance Sarcoma Research Grant $30,000 for one year
http://www.australiansarcomagroup.org/2018-sarcoma-research-grants.html